New Guidelines Reshape Care for Rare Bone Marrow Cancer Myelofibrosis

The American Society of Hematology has issued new evidence-based guidelines for managing myelofibrosis, a rare and life-threatening blood cancer in which scar tissue gradually replaces the blood-forming cells of the bone marrow. Published in the Society’s peer-reviewed journal Blood Advances, the guidance consists of ten recommendations developed by a multidisciplinary expert panel that included myelofibrosis and transplant specialists, methodology experts, and a patient and caregiver with lived experience. The recommendations span the full arc of care, from expanded molecular testing at diagnosis to the timing of stem cell transplant consultation, and they aim to close decision-making gaps that have long produced wide variation in how clinicians treat this uncommon disease.

Myelofibrosis belongs to a group of chronic blood cancers known as myeloproliferative neoplasms, in which the bone marrow overproduces different types of blood cells. In myelofibrosis specifically, the spongy interior of the bone that manufactures blood cells develops fibrotic scar tissue, progressively impairing its ability to produce enough healthy blood cells. The disease is rare, with estimates suggesting that up to six people per 100,000 are living with it. Despite its low prevalence, myelofibrosis carries serious consequences: individuals face an elevated risk of transformation to acute myeloid leukemia, as well as disease-related complications including enlargement of the spleen, the organ that helps fight infection and filter blood, and the development of blood clots.

For much of the modern treatment era, clinicians have relied on a relatively limited therapeutic arsenal. JAK inhibitors, a class of drugs that modulate signaling pathways driving the disease, can reduce spleen enlargement and ease other symptoms, and they remain the mainstay of pharmacologic management. The only potentially curative option, however, is allogeneic stem cell transplant, a procedure in which a patient’s faulty blood-forming cells are replaced with healthy stem cells from a donor. Because myelofibrosis is rare and its course can be unpredictable, approaches to treatment have historically varied substantially among clinicians, a problem the new guidelines were designed to address by synthesizing available evidence into practical, actionable recommendations.

Among the most consequential recommendations is extended molecular testing at diagnosis. Genetic profiling helps identify high-risk mutations that can inform prognosis and guide treatment selection, allowing clinicians to stratify patients more precisely than clinical criteria alone. The guidelines also call for early transplant consultation for higher-risk individuals who are receiving and responding to JAK inhibitors, a recommendation that reflects the delicate timing calculus of transplantation: referring too late can mean losing the window in which a patient is well enough to undergo the procedure, while referring patients who will never need it exposes them to unnecessary risk.

The guidance takes a nuanced position on JAK inhibitor use depending on disease risk. For lower-risk individuals with disease-related symptoms, the guidelines support the use of these agents to improve quality of life. Conversely, for higher-risk individuals without disease-related symptoms, the recommendations advise avoiding JAK inhibitors, a stance that underscores a central tension in myelofibrosis care: symptom relief must be weighed against disease control and the pursuit of curative intent in patients whose biology portends aggressive disease. This risk-adapted framework is one of the clearest signals the panel has sent about how personalized the management of this cancer should become.

Anemia receives dedicated attention in the guidelines, covering strategies for managing low blood counts that arise either from myelofibrosis itself or from JAK inhibitor therapy. Anemia is among the most burdensome manifestations of the disease, contributing to fatigue, transfusion dependence, and diminished survival, yet evidence for its optimal management has remained fragmented. By consolidating guidance in this area, the panel aims to give clinicians a more consistent framework for a problem that routinely complicates long-term treatment.

Another notable recommendation concerns low-dose aspirin for patients carrying the JAK2 V617F mutation, the most common genetic alteration in myelofibrosis. Because these patients face an elevated risk of blood clots, the guidelines address whether aspirin therapy can meaningfully reduce thrombotic complications in this specific molecular subgroup. The inclusion of a mutation-specific recommendation illustrates how deeply genetic testing now permeates the management of myeloproliferative neoplasms, extending beyond diagnosis and prognosis into preventive care.

Guideline panel chair Brady Stein, MD, professor of medicine at Northwestern University’s Feinberg School of Medicine, emphasized the practical intent behind the effort. According to Stein, the recommendations address questions that routinely come up for clinicians and patients managing myelofibrosis, and the hope is that they will enable hematologists to more confidently deliver better care to their patients. He also acknowledged that important gaps in evidence remain, expressing hope that the questions the panel asked can help set a future research agenda to further improve care for patients with this disease.

Indeed, the guidance explicitly identifies several areas where more research is needed. These include enhancing the prediction of which patients will benefit from specific treatments, establishing better approaches to myelofibrosis-related anemia, and clarifying the optimal timing for transplant. Each of these gaps reflects a broader challenge in rare-disease medicine: with limited patient populations, randomized trials are difficult to mount, and evidence often accrues slowly. By articulating a research agenda alongside its clinical recommendations, the panel has effectively mapped the frontier for the next generation of myelofibrosis studies.

For patients, the practical message is that the guidance clinicians use for treating myelofibrosis has changed. The new ASH guidelines emphasize individualized care based on a patient’s symptoms, spleen enlargement, anemia, genetic testing results, transplant eligibility, and personal preferences. Patients may want to ask their care team whether extended molecular testing is appropriate for them, whether a JAK inhibitor may help with symptoms or spleen enlargement, how anemia should be managed, and whether they should be referred for a stem cell transplant consultation. For those with the JAK2 V617F mutation, the guidelines also address the use of low-dose aspirin to help prevent blood clots. Additional resources, including snapshots, visual summaries, and teaching slides, are available through the Society’s website, offering patients and clinicians alike a shared foundation for navigating a disease that has long demanded more certainty than the evidence could provide.

Subject of Research: Clinical practice guidelines for the management of myelofibrosis, a rare bone marrow cancer

Article Title: ASH issues new recommendations to improve myelofibrosis care

Article References: ASH issues new recommendations to improve myelofibrosis care. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: myelofibrosis, American Society of Hematology, Blood Advances, JAK inhibitors, stem cell transplant, molecular testing, JAK2 V617F, anemia, aspirin, myeloproliferative neoplasm, clinical guidelines, hematology